Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02812524 · ClinicalTrials.gov registry record · Phase 1
Ipilimumab for Head and Neck Cancer Patients
A Phase 1 study of Squamous Cell Carcinoma of the Head and Neck, sponsored by Providence Health & Services.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT02812524: Active Phase 1 study of Squamous Cell Carcinoma of the Head and Neck, sponsored by Providence Health & Services.
NCT02812524 is a Phase 1 study of Squamous Cell Carcinoma of the Head and Neck that is active but no longer recruiting, run by Providence Health & Services. The registered enrollment target is 18 participants, below the 145-participant average among 29 other Squamous Cell Carcinoma of the Head and Neck trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02812524, a Phase 1 study of Squamous Cell Carcinoma of the Head and Neck, is active but no longer recruiting, sponsored by Providence Health & Services.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is for patients with squamous cell carcinoma of the head and neck (SCCHN). This study will test the feasibility of the administration of intratumoral injections of ipilimumab prior to surgical resection, and the immune system response to treatment.
Primary Outcome
The percentage of patients with surgery delayed possibly related to the study drug.
Conditions Studied
Interventions
- DRUG Intratumoral Ipilimumab
Study Locations (1)
Oregon
- Portland Providence Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-11-18 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What the registry record for NCT02812524 still lists
NCT02812524 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 145-participant average among 29 other Squamous Cell Carcinoma of the Head and Neck trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Squamous Cell Carcinoma of the Head and Neck appearing as the primary indexed condition, and to 1 intervention - of which Intratumoral Ipilimumab is the first listed.
NCT02812524 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT02812524 about?
NCT02812524 is a clinical study titled "Ipilimumab for Head and Neck Cancer Patients". This study is for patients with squamous cell carcinoma of the head and neck (SCCHN). This study will test the feasibility of the administration of intratumoral injections of ipilimumab prior to surgical resection, and the immune system response to treatment.
What is the current status of trial NCT02812524?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2016-11-18. Estimated completion is 2025-12.
What conditions does trial NCT02812524 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma of the Head and Neck.
What interventions are being tested in trial NCT02812524?
The interventions under investigation include: Intratumoral Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT02812524?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02812524 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma of the Head and Neck
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02812524's enrollment target sits among peer trials
18 27th of 29 higher than 3 of 29 other Squamous Cell Carcinoma of the Head and Neck trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Squamous Cell Carcinoma of the Head and Neck trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
RECRUITING · Phase 1
-
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
RECRUITING · Phase 1
-
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
RECRUITING · Phase 1
-
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
RECRUITING · Phase 1
-
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI